Arovella Therapeutics Ltd. is heading toward the clinic with its lead product, ALA-101, which consists of a chimeric antigen receptor (CAR) targeting CD19 and invariant natural killer T (iNKT) cells.
Hangzhou Jiuyuan Gene Engineering Co. Ltd. raised HKD$485.4 million (US$62.38 million) in a November 28 IPO on the main board of the Hong Kong Stock Exchange (HKEX:2566).
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Akeso, Alpha Biopharma, Astellas, Inxmed, Junshi, Leads Biolabs, Ractigen, Samsung Bioepis.
An international consortium of thousands of scientists is creating the Human Cell Atlas, a three-dimensional map of all the cells in the body. The goal is to understand all the cells that make up human tissues, organs and systems, which will enable multiple medical applications. This collection of cell maps is openly available for navigation at single-cell resolution, identified through omics analyses that reveal the tridimensional distribution of each cell.
Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: Avenzo, Beigene, Bristol Meyers Squibb, HCW Biologics, Intas, SK Biopharmaceuticals, Telix, Velavigo, WY Biotech, Xbrane.
RSS
